NSCLC Stage IV Clinical Trial
Official title:
A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations following targeted therapies.
In patients with an EGFR mutation, several phase III studies comparing EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy have shown a benefit of TKI over chemotherapy, with no demonstrated benefit on overall survival. After a first line of treatment with a TKI, most patients progress and are eligible according to the mechanism of progression to a TKI of 3rd generation in case of T790M resistance or chemotherapy. In patients with ALK translocation, crizotinib has been shown to be beneficial in first line compared to a platinum doublet.Despite these major advances, most patients are progressing after targeted treatments and chemotherapy and are facing the problem of anti-PD1 / PDL1 treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05543330 -
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04106180 -
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
|
Phase 2 | |
| Recruiting |
NCT05215548 -
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
|
Phase 2 | |
| Completed |
NCT04507217 -
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
|
Phase 2 | |
| Recruiting |
NCT04467801 -
Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT04027647 -
Phase 2 Study of Dacomitinib in NSCLC
|
Phase 2 | |
| Recruiting |
NCT04768491 -
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
|
||
| Not yet recruiting |
NCT04492969 -
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
|
||
| Recruiting |
NCT04116918 -
Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
|
||
| Terminated |
NCT03411473 -
Study of AGEN1884 With Pembrolizumab in 1L NSCLC
|
Phase 2 | |
| Recruiting |
NCT03564197 -
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
|
N/A | |
| Not yet recruiting |
NCT06219317 -
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT04604470 -
Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
|
||
| Recruiting |
NCT05132218 -
Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
|
||
| Not yet recruiting |
NCT04136535 -
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
|
Phase 2 | |
| Completed |
NCT03184571 -
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
|
Phase 2 | |
| Completed |
NCT06339554 -
Alectinib-induced Endocrine Toxicity
|
||
| Active, not recruiting |
NCT04549428 -
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
|
Phase 2 | |
| Recruiting |
NCT03647956 -
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
|
Phase 2 | |
| Recruiting |
NCT04180501 -
SRS Sequential Sindilimab in Brain Metastasis of NSLSC
|
Phase 2 |